Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.

NCT07177950 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT07177950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07177950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
September 30, 2029
Enrollment
51 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, breast cancer, leptomeningeal metastasis